Jiang Bian, PhD, was featured by The ASCO Post for a JAMA Oncology study examining the relationship between GLP-1 receptor agonist use and cancer risk in adults with overweight or obesity. The study found an overall reduced risk of cancer, including lower risks of endometrial, ovarian, and meningioma cancers, while also noting a potential increased risk of kidney cancer, underscoring the need for long-term follow-up.
-
Research
- Experts
In The News
View AllAP News features LOINC
LOINC, developed and maintained by the Regenstrief Institute, was featured by AP...
Influence
View AllPrimary Care and Survival: Implications for Research and Policy
Published in the Journal of General Internal Medicine. Here is a link...
- About
Regenstrief is dedicated to pioneering transformative solutions for a healthier world.
- The Latest
- Collaboration
Generating Evidence Across the Full Arc of Disease
Regenstrief Institute x Merck The Question Clinical trials establish whether...
Evaluating AI-Enabled Trial Screening in Real-World Oncology Workflows
Regenstrief, Triomics and Indiana University Health, supported by an independent...
- Experts



